Board summary
Key figures
45,769
Registered population
56.6% aged 18–64
24.0%
Aged 65+
ICB 21.9% · England 17.9%
7.8%
Ethnic minority (non-White)
3.8% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
8,677
Hypertension register
+6.76% in 3 yrs · England +5.60%
408
SMI register
29.5% of Mid Sussex's
832
COPD register
Reviews +24.79% in 3 yrs
Forecast to 2030
9,884
Hypertension patients, 2030
+1,207 on today
75.1%
QRISK ≥20% on statins, 2030
+6.00pp over 3 yrs
6.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 BP and high-risk lipid therapy lag.
Under-80 blood pressure control is 65.4% (England 67.8%; 3-year change -0.8% vs +3.2%) and high-risk lipid therapy is 61.0% (England 63.6%).
Age-five MMR2 and pre-school booster below target.
Age-five MMR drops 6.4 pp from dose 1 (95.4%) to dose 2 (89.0%), and the 4-in-1 booster is 88.1% against the 95.0% target.
Recent BP recording and chronic reviews exceed England.
Recent blood pressure recording reaches 93.3% (England 90.0%), with 80+ control at 81.4% (England 81.2%) and COPD annual reviews at 84.4% (England 76.4%).
Population, age and ethnicity
Older patients aged 65+ make up 24.0% of the PCN, exceeding England's 17.9%
Across 45,769 registered patients, 24.0% (11,004) are aged 65+, compared with 20.0% in Mid Sussex, 21.9% in NHS Sussex Integrated Care Board, and 17.9% in England. Across practices, Modality Mid Sussex has 27,615 patients with 25.0% aged 65+, while Moatfield Surgery has 18,154 patients with 22.6%. Resident Census data shows 92.2% White ethnicity (Mid Sussex 92.3%, ICB 91.0%, England 81.1%) and a 7.8% ethnic minority share, including 3.8% Asian or Asian British (Mid Sussex 3.6%, ICB 3.7%, England 9.6%). Census resident bases differ from registered lists.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Mid Sussex local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Mid Sussex LA) | 2,494 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 90.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Mid Sussex LA) | 1,184 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Mid Sussex LA) | 13.7 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.3 with zero registered patients in Core20 deciles
East Grinstead PCN has an average IMD decile of 8.3, matching Mid Sussex (8.3) and above NHS Sussex Integrated Care Board (6.1) and England (5.5). For Modality Mid Sussex (0.0%) and Moatfield Surgery (0.0%), 0.0% of registered patients live in Core20 areas (ICB 9.2%, England 21.0%). All 48 associated LSOAs sit above decile 2, giving 0 estimated Core20 residents. With zero Core20 concentration, inequalities work could focus on clinical inclusion cohorts rather than area indices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
408
SMI register
0.88% recorded prevalence
246
Learning disability register
0.53% recorded prevalence
27
Care homes, 798 beds
In the PCN catchment
7.9%
Provide unpaid care
Mid Sussex, Census 2021
The PCN records 408 severe mental illness patients (0.9% vs Mid Sussex 0.8%, ICB 1.1%, England 1.0%) and 246 learning disability patients (0.5% vs Mid Sussex 0.4%, ICB 0.6%, England 0.6%), alongside 27 catchment care homes (798 beds); catchment capacity does not establish resident counts. Crude recorded prevalence does not establish under-detection or unmet need, and care home bed capacity does not establish registered resident numbers.
Severe mental illness: physical health checks
Recorded SMI prevalence is 0.9% (408 patients). Captured checks show 87.3% had blood pressure recorded, 91.4% BMI and 85.8% alcohol. Smoking cessation offers fell 0.9 pp over three years (England +0.1 pp); uncaptured checks cannot imply complete reviews.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,677
Hypertension register
+6.76%
Register growth, 3 yrs
Mid Sussex +5.64% · England +5.60%
−0.56pp
BP control, under 80
≤140/90 · +6.27pp aged 80+
+1,207
More patients by 2030
Forecast 9,884 (21.36%)
Hypertension case-finding and control
Hypertension register prevalence is 18.7% (8,677 patients), above Mid Sussex (16.1%) and England (15.2%). Recent blood pressure recording reaches 93.3% (England 90.0%). While control in patients aged 80+ is 81.4% (England 81.2%), control in under-80s is 65.4%, below Mid Sussex (67.9%) and England (67.8%), having fallen 0.8% over three years (England +3.2%). Under-80 control is 64.9% at Modality Mid Sussex and 66.4% at Moatfield Surgery; denominators include personalised care adjustments. Under-80 blood pressure control trails national rates despite high measurement coverage, which may reflect titration or adherence gaps to test via recall audit.
Lipids and statins
For high-risk cardiovascular prevention, lipid-lowering therapy reaches 61.0% in patients with QRISK ≥ 20% (England 63.6%) and 66.8% in CKD (England 70.3%). Secondary prevention statin treatment in diabetes with CVD is 79.5%, trailing England (84.4%). Structured statin initiation audits could address these treatment gaps.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 69,478 | £2.20 | £2.42 | £1.86 | £152,852 |
| Cardiovascular (all), 2025 | 96,391 | £3.67 | £3.32 | £3.33 | £353,755 |
In 2026, 69,478 items of lipid-regulating drugs cost £2.20 per item (England £1.86; NHS Sussex Integrated Care Board £2.42). Spend was £23,623 more than at England's unit cost, but £15,285 less than at NHS Sussex Integrated Care Board's unit cost. Unit cost differences reflect local formulary choices and do not establish prescribing inefficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+24.57%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.19%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.3% (3,197 patients; England 6.6%). Annual reviews grew +24.6% over three years (England +4.4%) to 68.6% (England 65.7%), leaving about 1,000 unreviewed patients; Modality Mid Sussex reached 58.6% and Moatfield Surgery 83.1%. COPD prevalence is 1.8% (832 patients; England 1.9%), with reviews rising +24.8% over three years (England +2.8%) to 84.4% (England 76.4%). Paediatric asthma prescribing is 1,021 rate per 1,000 (England 1,488 rate). Prioritising asthma review recall at Modality Mid Sussex could address unreviewed cases.
Cancer register and children's immunisation
Cancer register prevalence is 5.4% (2,493 patients; England 3.8%). In Q1 2025/26 childhood immunisations, 6-in-1 coverage at 12 months is 97.5% (England 91.0%), and MMR dose 1 at 24 months is 88.8% (England 88.3%). At age 5, a 6.4 pp gap separates MMR dose 1 (95.4%) and dose 2 (89.0%, below the 95.0% target by 6 pp). Pre-school 4-in-1 booster reaches 88.1% (target 95.0%). Second-dose pre-school recall is the key operational priority.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
Across NHS Sussex ICB in 2022, 58.5% of staged cancers were detected at stage 1 or 2 (4,799 of 8,209), above England (55.3%) but below the 75.0% national ambition by 2028 by 16.5 pp. Staged cancers represented 64.3% of 12,766 registered ICB cancers (England 67.0%), requiring about 1,360 additional early diagnoses ICB-wide annually. Early detection was lowest in oesophagus (24.1%) and lung (30.3%). While ICB staging reflects wider system pathways, PCN cervical screening is 72.3%, ranging from 69.6% at Modality Mid Sussex to 76.4% at Moatfield Surgery.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Surrey and Sussex Healthcare NHS Trust achieved 70.0% on the 62-day cancer standard, below the 85.0% target by 15.0 pp, while University Hospitals Sussex NHS Foundation Trust reached 65.2%, Maidstone and Tunbridge Wells NHS Trust 87.4%, NHS Surrey and Sussex Integrated Care Board 71.5%, and England 71.2%. The trust met the 28-day faster diagnosis standard at 77.7% and the 31-day combined standard at 96.2%. Diagnostic waits include 28.5% of patients waiting 6+ weeks across all tests at Surrey and Sussex Healthcare NHS Trust (England 23.1%), including 43.8% for echocardiography and 32.3% for non-obstetric ultrasound.
| Pathways within standard (%) | Surrey and Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.74 | 74.01 | 81.78 | 79.29 | 79.32 |
| 31-day treatment (96%) | 96.20 | 76.79 | 98.35 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 69.97 | 65.20 | 87.43 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Surrey and Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 27.53 | 5.62 | 0.92 | 21.40 |
| CT | 18.49 | 8.57 | 0.51 | 9.92 |
| Echocardiography | 43.78 | 0.39 | 2.57 | 28.48 |
| Colonoscopy | 15.11 | 39.35 | 19.80 | 30.83 |
| Gastroscopy | 21.06 | 20.02 | 24.03 | 29.02 |
| All 15 DM01 tests | 28.50 | 12.95 | 6.42 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026, West Sussex recorded 78,050 community care contacts across 19,770 patients, alongside 16,015 referrals. Across NHS Surrey and Sussex Integrated Care Board, 309,615 contacts were recorded for 85,660 patients. Adults aged 65+ accounted for 72.7% of West Sussex residents' contacts (56,740). These experimental data describe local authority and ICB activity rather than PCN caseloads.
Practice variation and patient experience
Easy phone access spans 21.0% to 51.9% across the PCN's two practices
In 2025/26, overall QOF achievement was 95.2% at Moatfield Surgery against an England average of 92.5%, whereas Modality Mid Sussex achieved 89.7%. Clinical achievement reached 100.0% at Moatfield Surgery (England 97.1%), while Modality Mid Sussex reached 96.5%. Vaccination and immunisation achievement diverged by 20.8 pp: Moatfield Surgery achieved 57.4% (England 55.2%), compared with 36.6% at Modality Mid Sussex.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Moatfield Surgery | 101 | 0.0 | 51.9% | 69.8% | 79.9% |
| Modality Mid | 104 | 0.0 | 21.0% | 48.3% | 51.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Asthma reviews rose 24.6% while blood pressure control fell 0.8% over three years
Over three years, the PCN’s widest lags against England are in breast screening coverage, which rose 1.6% (England +8.4%), and under-80 blood pressure control, which fell 0.8% (England +3.2%), alongside heart failure reviews rising 6.5% (England +8.7%). By contrast, recorded annual reviews improved substantially: COPD reviews grew 24.8% (England +2.8%) and asthma reviews rose 24.6% (England +4.4%). Furthermore, physical health checks for patients with severe mental illness showed notable three-year gains, including alcohol recording rising 18.9 pp (England +5.4 pp) and blood pressure checks rising 14.9 pp (England +4.4 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Breast screening (53-70)
BP control, under 80
COPD register
Heart failure reviews
Smoking support (SMI)
COPD reviews
Asthma reviews
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Mid Sussex | Asset | PCN | Mid Sussex |
|---|---|---|---|---|---|
| Care homes (catchment) | 27 (798 beds) | n/a | Schools (catchment) | 54 | n/a |
| Children's centres | 6 | 8 | Places of worship | 46 | 95 |
| Libraries | 1 | 4 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 2 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 15 | 19 | Primary academies | 10 | 22 |
| Special schools | 2 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall audit
Across 3,197 asthma patients, annual review coverage is 68.6% (Mid Sussex 66.3%; England 65.7%), leaving about 1,000 (1,004) patients without a recorded review. For discussion: run a structured asthma review recall using a common template, starting at Modality Mid Sussex where recorded review coverage is 58.6%. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension and lipid review
Across 8,677 hypertension patients, under-80 BP control is 65.4% (Mid Sussex 67.9%; England 67.8%; 3-year change -0.8% vs England +3.2%), while QRISK >= 20% lipid therapy is 61.0% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 109), age-five MMR dose 2 is 89.0% (below the 95.0% target by 6 pp and 6.4 pp below dose 1 at 95.4%), with 4-in-1 booster at 88.1%. For discussion: audit age-five cohorts for missing second MMR and 4-in-1 booster doses and test flexible clinic times. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Inclusion health clinical targeting (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation support review (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension control recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school second dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review recall audit (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Under-80 hypertension and lipid review (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Pre-school booster and MMR2 recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
